COYA Graph | Coya Therapeutics, Inc.

COYA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $243.75K; Operating expenses $7.29M; Income tax (m); Net income -$6.64M.
2026-03-31: Revenue $251.15K; Operating expenses $7.89M; Income tax (m); Net income -$7.21M.
2025-12-31: Revenue $3.96M*; Operating expenses $9.99M*; Income tax (m); Net income -$5.71M*.
2025-09-30: Revenue $3.56M; Operating expenses $6.00M; Income tax (m); Net income -$2.12M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Operating expenses	Income tax	Net income
2026-06-30	$243.75K	$7.29M	(m)	-$6.64M
2026-03-31	$251.15K	$7.89M	(m)	-$7.21M
2025-12-31	$3.96M*	$9.99M*	(m)	-$5.71M*
2025-09-30	$3.56M	$6.00M	(m)	-$2.12M
2025-06-30	$163.62K	$6.58M	$0.00	-$6.09M
2025-03-31	$257.88K	$7.93M	(m)	-$7.31M
2024-09-30	$0.00	$4.45M	(m)	-$4.02M
2024-06-30	$3.43M	$6.66M	$0.00	-$2.89M
2024-03-31	$126.84K	$5.61M	(m)	-$5.05M
2023-09-30	$0.00	$3.56M	(m)	-$3.42M
2023-06-30	$0.00	$3.25M	(m)	-$3.10M
2023-03-31	$0.00	$2.90M	(m)	-$2.74M
2022-09-30	(m)	$2.66M	(m)	-$4.02M
2022-06-30	(m)	$3.45M	(m)	-$3.41M
2022-03-31	(m)	$1.70M	(m)	-$1.70M

Revenue and expense 6 month

Period end	Revenue	Operating expenses	Income tax	Net income
2026-06-30	$494.89K	$15.18M	(m)	-$13.85M
2025-06-30	$421.50K	$14.51M	$0.00	-$13.40M
2024-06-30	$3.55M	$12.27M	$0.00	-$7.94M
2023-06-30	$0.00	$6.15M	(m)	-$5.83M
2022-06-30	(m)	$5.15M	(m)	-$5.12M

Revenue and expense 9 month

Period end	Revenue	Operating expenses	Net income
2025-09-30	$3.99M	$20.51M	-$15.52M
2024-09-30	$3.55M	$16.72M	-$11.97M
2023-09-30	$0.00	$9.72M	-$9.25M
2022-09-30	(m)	$7.81M	-$9.14M

Revenue and expense 12 month

Period end	Revenue	Operating expenses	Income tax	Net income
2025-12-31	$7.95M	$30.50M	$3.09K	-$21.23M
2024-12-31	$3.55M	$20.80M	-$720.29K	-$14.88M
2023-12-31	$6.00M	$13.91M	$723.85K	-$7.99M
2022-12-31	$0.00	$9.81M	$0.00	-$12.24M
2021-12-31	(m)	$4.87M	(m)	-$4.89M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
CUMBERLAND PHARMACEUTICALS INC (CPIX)	United States	$0.121B	-8.95
Aardvark Therapeutics, Inc. (AARD)	United States	$0.121B	-1.80
OnKure Therapeutics, Inc. (OKUR)	United States	$0.119B	-3.13
INOVIO PHARMACEUTICALS, INC. (INO)	United States	$0.125B	-1.35
IMMUNIC, INC. (IMUX)	United States	$0.127B	-1.88
Immuneering Corp (IMRX)	United States	$0.113B	-12.51
Quantum Cyber N.V. (QUCY)		$0.113B
BICYCLE THERAPEUTICS PLC (BCYC)		$0.112B	-1.56
MEDICINOVA INC (MNOV)	United States	$0.130B	-6.04
NRX Pharmaceuticals, Inc. (NRXP)	United States	$0.131B	-6.31